Accendra Health Inc/Va/ (ACH) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Trading Companies & Distributors · as of Aug 12, 2026
Accendra Health Inc/Va/ (ACH)
A forensic read on Accendra Health Inc/Va/ built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-2.3
Distress distance
Clean
Earnings quality
5
Forensic signals
$261M
Market cap
3.1%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Accendra Health Inc/Va/ earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -2.3, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
1.5%
FY2025
Return on invested capital.Return on invested capital is 1.5% in the latest fiscal year and slipping from 3% — well below its ~8% cost of capital, so reinvested dollars may be destroying value, not building it.
FCF ($293M)
FY2025
Shareholder returns.Returned $10M to shareholders (buybacks + dividends) in FY2025, but free cash flow was ($293M) after capex — there was no free cash flow to fund the payout from at all, and operating cash flow itself was negative or zero that year too. The entire return is coming from debt or cash reserves, not cash the business itself generated — a harder case than returns merely running ahead of free cash flow, since here there was none to run ahead of.
suspended
FY2021→FY2023
Dividend — suspended.The dividend has been SUSPENDED — $731,000 paid in FY2021, then $0 in FY2023. A suspension is a major signal the board is conserving cash; the prior payment history doesn't offset it.
+0.3%/yr
FY2022–FY2025
Share count.Diluted share count changed +1% over the last 3 years to FY2025 (+0.3%/yr). Roughly flat — buybacks ($10M) are about offsetting stock comp ($13M), not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.
$307M
FY2024–FY2024
Goodwill impairments.Took $307M of goodwill writedowns across 1 year (FY2024 ($307M)). Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$2.76B
Revenue Growth YoY+3.1%
Net Margin-39.8%
Free Cash Flow-$292.7M
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Accendra Health Inc/Va/'s actual 10-K/10-Q/8-K filings?